Blood Protein Colors Fake Meat: FDA Gives Green Light
Published Date: 5/29/2025
Rule
Summary
The FDA is making it official: starting February 19, 2025, myoglobin can be safely used as a color additive in ground meat and plant-based meat alternatives. This change affects food makers who want to add natural color to their products, helping them look fresh and tasty without extra hassle. No big costs are expected, just a new way to keep your favorite foods looking great!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Myoglobin Allowed for Ground Meat Makers
Starting February 19, 2025, the FDA allows myoglobin to be used as a color additive in ground meat and ground poultry analogue products. This change affects food makers who want to add natural color to those products and provides a regulatory path to use myoglobin safely.
Shoppers May See Fresher-Looking Products
Because myoglobin is allowed as a color additive effective February 19, 2025, ground meat and ground poultry analogue products may appear fresher or more meat-like in color. The FDA confirms this safe-use listing for those specific product types.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-09679 — Florylpicoxamid; Pesticide Tolerances
The EPA is setting safe limits for florylpicoxamid pesticide residues on several foods, thanks to a request from Corteva Agriscience. This means farmers and food producers can use this pesticide within these new rules to keep food safe. These changes help protect consumers without adding extra costs or delays.
Next: 2025-09692 — Endangered and Threatened Wildlife and Plants; Removal of Colorado Hookless Cactus From the List of Endangered and Threatened Plants
Great news! The U.S. Fish and Wildlife Service is officially removing the Colorado hookless cactus from the endangered list because it’s doing much better now. This means fewer rules and protections are needed, saving money and letting nature take its course. The change affects both types of this cactus and shows how smart science helps us celebrate success in protecting plants.